Loading
A phase 1/2 trial of Azacitidine, Venetoclax and Obinutuzumab in acute myeloid leukaemia, run by Molecular Partners AG, active and no longer recruiting.
Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome is a phase 1/2 interventional study registered as NCT05673057 by Molecular Partners AG, with 249 participants enrolled, started 2022-12-29 and due to reach its primary completion in 2026-05-29. Interventions recorded: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1, MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A, MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclax, MP0533 with Obinutuzumab pretreatment, MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B relapsed/refractory AML and MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B in treatment naïve patients.
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
Shares Molecular Partners and the tag pipeline.
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.